EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 327 filers reported holding EXELIXIS INC in Q4 2021. The put-call ratio across all filers is 1.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,480,318 | +5.5% | 426,657 | -5.9% | 0.22% | +18.6% |
Q2 2023 | $8,988,806 | -11.9% | 453,522 | -13.7% | 0.18% | -11.6% |
Q1 2023 | $10,197,800 | -40.5% | 525,389 | -50.8% | 0.21% | -40.9% |
Q4 2022 | $17,125,026 | -8.4% | 1,067,645 | -10.5% | 0.35% | -9.8% |
Q3 2022 | $18,703,000 | -37.4% | 1,192,816 | -16.9% | 0.39% | -34.5% |
Q2 2022 | $29,888,000 | -8.1% | 1,435,566 | +0.0% | 0.59% | +13.8% |
Q1 2022 | $32,532,000 | +20.4% | 1,435,014 | -2.9% | 0.52% | +32.7% |
Q4 2021 | $27,010,000 | -0.3% | 1,477,597 | +15.4% | 0.39% | -3.0% |
Q3 2021 | $27,079,000 | +14.3% | 1,280,924 | -1.5% | 0.40% | +14.8% |
Q2 2021 | $23,693,000 | +140.4% | 1,300,375 | +198.0% | 0.35% | +137.8% |
Q1 2021 | $9,856,000 | -55.9% | 436,302 | -60.8% | 0.15% | -63.9% |
Q4 2020 | $22,339,000 | +32.3% | 1,113,052 | +61.1% | 0.41% | +9.3% |
Q3 2020 | $16,890,000 | +45.9% | 690,796 | +32.1% | 0.38% | +34.9% |
Q1 2018 | $11,579,000 | -34.8% | 522,761 | -10.5% | 0.28% | -36.7% |
Q4 2017 | $17,758,000 | – | 584,159 | – | 0.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |